ArticleJournal of robotic surgery2025
Extraperitoneal robot-assisted radical prostatectomy with the Hugo™ RAS system: 100 consecutive cases, 1-year follow-up and surgical learning curve evaluation.
Article in Journal of robotic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hugo™ RAS versus da VinciBMC surgery · 2026Pooled it
- Hugo RAS Versus Da Vinci in Colorectal Surgery: A Systematic Review and Outcome Meta-Analysis.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Hugo™ Robotic-Assisted Surgery (RAS) system is an emerging robotic platform; evidence on its performance for extraperitoneal robot-assisted radical prostatectomy (eRARP) remains limited. Between June 2023 and September 2024, 100 patients with prostate cancer underwent eRARP using the Hugo™ RAS system. Preoperative, intraoperative, pathological and postoperative data were collected prospectively. To assess temporal trends related to platform adoption, the cohort was divided into the first 50 and last 50 cases and learning-curve dynamics were analyzed (including CUSUM for console time). We report 12-month follow-up. Across the entire series, the median operative duration was 252.5 min (Q1-Q3 200-290), with no instances of intraoperative conversion or intraoperative complications. Major postoperative events classified as Clavien-Dindo grade III or higher were observed in 2% of patients. At the 12-month assessment, an undetectable PSA (< 0.1 ng/mL) was documented in 80% of individuals, social continence (≤ 1 pad per day) in 87%, and erectile function recovery in 51%. Overall positive surgical margin (PSM) rate was 40%, with clinically significant PSM (≥ 3 mm or multifocal) of 21%. Comparison of two groups revealed a learning effect: median operative time decreased from 275 to 210 min (p < 0.00001); docking time improved modestly (p = 0.0271). Both clinically significant PSMs (28%→14%) and overall complication rates (26%→4%, p = 0.0006) declined in the second cohort. In this prospective, single-center series, eRARP using the Hugo™ RAS system was feasible and safe. A learning-curve effect produced substantially shorter operative times and fewer complications, while oncological and functional outcomes were preserved. Longer follow-up and larger multicenter studies are needed to verify long-term equivalency with well-established robotic platforms.
Indexed as
Identifiers
41460295What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.